伊木萨克通过调节人血清PF4和CXCL7水平改善勃起功能障碍  

Imusak Improves Erectile Dysfunction by Regulating Human Serum PF4 and CXCL7 Levels

作　　者：金秀芳 牛立盼 郭浩强 朱兵兵 刘凤霞 JIN Xiufang;NIU Lipan;GUO Haoqiang;ZHU Bingbing;LIU Fengxia(Department of Human Anatomy,School of Basic Medical Sciences,Xinjiang Medical University,Urumqi,Xinjiang Uygur Autonomous Region,830011 China)

机构地区：[1]新疆医科大学基础医学院人体解剖学教研室,新疆乌鲁木齐830011

出　　处：《系统医学》2021年第17期19-22,34,共5页Systems Medicine

基　　金：国家自然科学基金(81860781);自治区自然科学计划(自然科学基金)联合基金项目(2021D01C280)。

摘　　要：目的研究勃起功能障碍(ED)患者血清血小板因子4(PF4)和趋化因子配体7(CXCL7)含量变化,并检测伊木萨克治疗后对上述蛋白血清含量的影响。方法选择2015年5月—2017年4月在新疆医科大学第一、第四附属医院男科确诊ED患者228例,从中随机筛选仅采用伊木萨克治疗的患者40例(M组),并选择正常健康人36名(N组)。采用酶联免疫吸附法检测伊木萨克片治疗前后人血清PF4和CXCL7含量。结果该研究发现M组治疗前后、N组人血清PF4、CXCL7的浓度比较差异有统计学意义(F=5.513、41.463,P<0.05)。其中,治疗前患者血清PF4浓度(1.55±0.59)μg/mL,CXCL7浓度(4.97±0.03)μg/mL,与N组血清PF4、CXCL7浓度相比,治疗前患者血清PF4、CXCL7浓度分别增加124.6%、8.7%,差异有统计学意义(P<0.05)。经伊木萨克治疗后,患者血清PF4浓度为(0.98±0.60)μg/mL,CXCL7浓度为(4.65±0.25)μg/mL,与N组相比,其血清PF4、CXCL7浓度分别增加42.0%、1.8%,差异无统计学意义(P>0.05)。与治疗前相比,治疗后患者血清PF4、CXCL7含量分别降低58.2%、6.4%,差异有统计学意义(P<0.05)。结论伊木萨克可能通过调节人血清PF4和CXCL7水平,有效改善ED的发生发展,其具体机制还有待进一步研究。Objective To study the changes of serum platelet factor 4(PF4)and chemokine ligand 7(CXCL7)levels in patients with erectile dysfunction(ED),and to detect the effects of Imusak treatment on the serum levels of these proteins.Methods From May 2015 to April 2017,228 patients with ED diagnosed in the Andrology Department of the First and Fourth Affiliated Hospitals of Xinjiang Medical University were selected.Among them,40 patients who were treated with Imusak were randomly selected(group M),and 36 normal healthy people were selected(group N).Enzyme-linked immunosorbent assay was used to detect the levels of PF4 and CXCL7 in human serum before and after treatment with Yimuzake tablets.Results The study found that there were statistically significant differences in the human serum PF4 and CXCL7 concentrations between the M group before and after treatment and N group(F=5.513,41.463,P<0.05).Among them,the serum PF4 concentration of patients before treatment(1.55±0.59)μg/mL,and the CXCL7 concentration(4.97±0.03)μg/mL,compared with the serum PF4 and CXCL7 concentrations of the N group,the serum PF4 and CXCL7 concentrations of the patients before treatment increased by 124.6%and 8.7%respectively,and the difference was statistically significant(P<0.05).After treatment with Imusak,the serum PF4 concentration of the patient was(0.98±0.60)μg/mL,and the CXCL7 concentration was(4.65±0.25)μg/mL.Compared with the N group,the serum PF4 and CXCL7 concentrations were respectively increased by 42.0%,1.8%,the difference was not statistically significant(P>0.05).Compared with that before-treatment,the serum PF4 and CXCL7 levels after treatment decreased by 58.2%and 6.4%,respectively,and the difference was statistically significant(P<0.05).Conclusion Imusak may effectively improve the occurrence and development of ED by regulating the levels of PF4 and CXCL7 in human serum,and the specific mechanism remains to be further studied.

关 键 词：勃起功能障碍 伊木萨克 血小板因子4 趋化因子配体7 

分 类 号：R698[医药卫生—泌尿科学]